Pfizer stock (US7170811035): Surpasses Q1 earnings, reaffirms 2026 guidance

Pfizer reported Q1 revenues of $14.5 billion and adjusted EPS of $0.75, beating estimates, while confirming 2026 sales outlook of $59.5-62.5 billion.

Pfizer released its first-quarter 2026 earnings on May 10, 2026, surpassing analyst expectations with adjusted earnings per share of $0.75 compared to the forecasted $0.72 and revenues of $14.5 billion against estimates of $13.84 billion, GuruFocus as of May 10, 2026. The company reaffirmed its full-year 2026 revenue guidance of $59.5 billion to $62.5 billion. This performance underscores ongoing operational strength amid a shifting pharmaceutical landscape.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Pfizer Inc.
• Sector/industry: Pharmaceuticals / Biotechnology
• Headquarters/country: United States
• Core markets: Global, with strong US presence
• Key revenue drivers: Oncology, vaccines, internal medicine
• Home exchange/listing venue: NYSE (PFE)
• Trading currency: USD

Pfizer Inc.: core business model

Pfizer Inc. operates as a leading biopharmaceutical company, focusing on discovering, developing, and manufacturing innovative medicines and vaccines. Its portfolio spans oncology, immunology, rare diseases, and internal medicine, serving patients worldwide. The company invests heavily in R&D, with key products like Eliquis, Ibrance, and Prevnar driving sustained growth, particularly relevant for US investors given its NYSE listing and substantial domestic revenue exposure.

Main revenue and product drivers for Pfizer Inc.

Pfizer's revenue is primarily generated from blockbuster drugs including Eliquis for cardiovascular disease and Prevnar family for pneumococcal disease, which together account for a significant portion of sales. Oncology products like Ibrance and Padcev contribute meaningfully, while the ongoing transition from COVID-19 products like Comirnaty and Paxlovid impacts near-term figures but supports long-term diversification. Q1 2026 revenues of $14.5 billion reflect resilient demand in core areas, as reported on May 10, 2026, GuruFocus as of May 10, 2026.

Industry trends and competitive position

The pharmaceutical sector faces pressures from patent expirations and biosimilar competition, yet Pfizer maintains a strong position through its pipeline of over 100 projects in development. Strategic acquisitions like Seagen have bolstered its oncology franchise, positioning it competitively against peers like Merck and Roche. For US investors, Pfizer's exposure to the world's largest pharma market enhances its appeal amid rising demand for innovative therapies.

Why Pfizer Inc. matters for US investors

As a NYSE-listed giant with deep roots in the US healthcare system, Pfizer influences American markets through its contributions to vaccine programs and chronic disease treatments. Its products are integral to Medicare and private insurance formularies, tying performance to US economic health and policy shifts like drug pricing reforms.

Conclusion

Pfizer's Q1 beat and reaffirmed 2026 guidance signal operational resilience, with core products offsetting pandemic-related declines. Investors track pipeline progress and acquisition integration for future growth. The company's US-centric revenue base remains a key factor in its market relevance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.